Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Jun 27, 2018 04:14PM Form SC 13D/A RHYTHM PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jun 22, 2018 04:02PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jun 21, 2018 07:30AM Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
Jun 18, 2018 04:05PM Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
Jun 15, 2018 04:05PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 6, 2018 06:11PM Form 4 Adaptimmune Therapeutics For: Jun 04 Filed by: ORBIMED ADVISORS LLC
Jun 4, 2018 05:23PM Form SC 13D/A RHYTHM PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jun 1, 2018 05:26PM Form 4 Adaptimmune Therapeutics For: May 30 Filed by: ORBIMED ADVISORS LLC
May 29, 2018 04:14PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
May 24, 2018 04:15PM Form 4 RHYTHM PHARMACEUTICALS, For: May 22 Filed by: ORBIMED ADVISORS LLC
May 21, 2018 06:16PM Form 4 RHYTHM PHARMACEUTICALS, For: May 18 Filed by: ORBIMED ADVISORS LLC
May 16, 2018 05:23PM Form 4 Adaptimmune Therapeutics For: May 14 Filed by: ORBIMED ADVISORS LLC
May 15, 2018 04:29PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 9, 2018 09:22PM Form 4 Inspire Medical Systems, For: May 07 Filed by: ORBIMED ADVISORS LLC
May 8, 2018 04:21PM Natera Reports First Quarter 2018 Financial Results
May 7, 2018 08:35AM ORIC Has Appointed Jacob Chacko, MD as Chief Executive Officer
May 2, 2018 09:35PM Form 3 Inspire Medical Systems, For: May 02 Filed by: ORBIMED ADVISORS LLC
May 2, 2018 05:16PM Form 4 ORBIMED ADVISORS LLC For: Apr 30 Filed by: PIERIS PHARMACEUTICALS, INC.
May 2, 2018 04:58PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
May 2, 2018 08:00AM Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growth
May 1, 2018 04:10PM Form SC 13D/A SteadyMed Ltd. Filed by: ORBIMED ADVISORS LLC
Apr 12, 2018 11:56AM Form SC 13D/A SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
Apr 9, 2018 08:00AM Cydan Appoints Chief Business Officer
Mar 29, 2018 06:55PM Form 4 ORBIMED ADVISORS LLC For: Mar 27 Filed by: Adaptimmune Therapeutics PLC
Mar 29, 2018 05:25PM Form SC 13D/A Adaptimmune Therapeutics Filed by: ORBIMED ADVISORS LLC
Mar 28, 2018 07:00AM Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial Results
Mar 19, 2018 08:00AM PMV Pharma Appoints Salim Yazji, M.D. as Chief Medical Officer
Mar 14, 2018 04:26PM Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Mar 14, 2018 01:59PM Form 4 ORBIMED ADVISORS LLC For: Mar 12 Filed by: Corvus Pharmaceuticals, Inc.
Mar 14, 2018 10:07AM WallachBeth Capital, LLC Acts as the Sole Placement Agent for SmartZyme's Ongoing Series B-1 Offering
Mar 13, 2018 04:30PM Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results
Mar 12, 2018 06:16PM Form 4 ORBIMED ADVISORS LLC For: Mar 08 Filed by: Audentes Therapeutics, Inc.
Mar 6, 2018 07:36PM Form 4 ORBIMED ADVISORS LLC For: Mar 02 Filed by: GLAUKOS Corp
Mar 6, 2018 05:53PM Form 4 ORBIMED ADVISORS LLC For: Mar 02 Filed by: Audentes Therapeutics, Inc.
Mar 6, 2018 12:16PM Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 23, 2018 06:55PM Form 4 Xtant Medical Holdings, For: Feb 14 Filed by: ORBIMED ADVISORS LLC
Feb 21, 2018 04:47PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Feb 16, 2018 01:25PM Form SC 13D/A Intellia Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 15, 2018 05:02PM Form 4 ORBIMED ADVISORS LLC For: Feb 13 Filed by: PIERIS PHARMACEUTICALS, INC.
Feb 15, 2018 04:40PM Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
Feb 14, 2018 05:50PM Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
Feb 13, 2018 04:56PM Form SC 13G/A Xenon Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
Feb 13, 2018 04:55PM Form SC 13G/A SYNERGY PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2018 04:55PM Form SC 13G Sierra Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2018 04:55PM Form SC 13G/A Wright Medical Group Filed by: ORBIMED ADVISORS LLC
Feb 13, 2018 04:54PM Form SC 13G/A ProQR Therapeutics N.V. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2018 04:54PM Form SC 13G/A ObsEva SA Filed by: ORBIMED ADVISORS LLC
Feb 13, 2018 04:54PM Form SC 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2018 04:53PM Form SC 13G/A NEWLINK GENETICS CORP Filed by: ORBIMED ADVISORS LLC
Feb 13, 2018 04:51PM Form SC 13G/A ROCKET PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed